Disc Net Income From Continuing Ops from 2010 to 2024

IRON Stock   64.96  1.45  2.28%   
Disc Medicine Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to about -67.3 M. During the period from 2010 to 2024, Disc Medicine Net Loss quarterly data regression pattern had range of 31 M and standard deviation of  11,143,153. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-64.1 M
Current Value
-67.3 M
Quarterly Volatility
11.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Disc Medicine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Disc Medicine's main balance sheet or income statement drivers, such as Net Interest Income of 11 M, Interest Income of 11 M or Depreciation And Amortization of 140.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.92. Disc financial statements analysis is a perfect complement when working with Disc Medicine Valuation or Volatility modules.
  
Check out the analysis of Disc Medicine Correlation against competitors.
To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.

Latest Disc Medicine's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Disc Medicine over the last few years. It is Disc Medicine's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Disc Medicine's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Disc Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(46,619,713)
Coefficient Of Variation(23.90)
Mean Deviation8,481,313
Median(40,837,000)
Standard Deviation11,143,153
Sample Variance124.2T
Range31M
R-Value(0.69)
Mean Square Error70.7T
R-Squared0.47
Significance0
Slope(1,710,185)
Total Sum of Squares1738.4T

Disc Net Income From Continuing Ops History

2024-67.3 M
2023-64.1 M
2022-46.8 M
2021-71.9 M

About Disc Medicine Financial Statements

Disc Medicine investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Disc Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-64.1 M-67.3 M

Pair Trading with Disc Medicine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Disc Medicine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Disc Medicine will appreciate offsetting losses from the drop in the long position's value.

Moving against Disc Stock

  0.8PFE Pfizer Inc Aggressive PushPairCorr
  0.77TCHH Trustcash HoldingsPairCorr
  0.75JNJ Johnson Johnson Sell-off TrendPairCorr
  0.66MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.61ME 23Andme HoldingPairCorr
The ability to find closely correlated positions to Disc Medicine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Disc Medicine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Disc Medicine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Disc Medicine to buy it.
The correlation of Disc Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Disc Medicine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Disc Medicine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Disc Medicine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Disc Medicine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Disc Medicine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Disc Medicine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Disc Medicine Stock:
Check out the analysis of Disc Medicine Correlation against competitors.
To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Disc Medicine. If investors know Disc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Disc Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.95)
Return On Assets
(0.18)
Return On Equity
(0.25)
The market value of Disc Medicine is measured differently than its book value, which is the value of Disc that is recorded on the company's balance sheet. Investors also form their own opinion of Disc Medicine's value that differs from its market value or its book value, called intrinsic value, which is Disc Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Disc Medicine's market value can be influenced by many factors that don't directly affect Disc Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Disc Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.